XBIvsXPH
SPDR S&P Biotech ETF against SPDR S&P Pharmaceuticals ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| XBI | XPH | |
|---|---|---|
| Expense ratio | 0.35% | 0.35% |
| Assets | $10.4B | $524M |
| Net flow, 1 month | −$690M | −$15M |
| Net flow, 1 year | +$1.1B | +$274M |
| Return, YTD | +26.7% | +13.9% |
| Return, 1 year | +52.4% | +31.4% |
| Avg daily volume | 8.6M | 170K |
| Holdings | 135 | 41 |
| Listed | Jan 31, 2006 | Jun 19, 2006 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS